A score based on three routine blood tests may help identify people with pulmonary hypertension (PH) who are at higher risk of dying or being hospitalized for heart failure within about a year, a study in Turkey suggests. The platelet–albumin–bilirubin index, or PALBI, helped distinguish people…
News
The American College of Chest Physicians (CHEST) is launching a first-of-its-kind education and certification program for nurse practitioners (NPs) and physician assistants/associates (PAs) who are interested in treating people with lung diseases such as pulmonary hypertension. CHEST announced the program after completing a comprehensive discovery initiative examining…
Liquidia and United Therapeutics have entered into a global settlement that ends a yearslong legal dispute over Yutrepia, Liquidia’s dry powder inhalation formulation of the medication treprostinil. Under the settlement, Liquidia will maintain access to Yutrepia for people with pulmonary arterial hypertension (PAH), but pull the…
Over the past three decades, rates of pulmonary arterial hypertension (PAH) have increased in wealthy parts of the world, including the U.S. and Europe — but though the rare disease has become more common in richer nations, the rates of death due to PAH have nonetheless decreased over time…
A marker on a CT scan could help identify pulmonary fibrosis patients who need further evaluation for pulmonary hypertension (PH), a study found. Among people with progressive pulmonary fibrosis, PH was linked to a larger pulmonary artery-to-aorta (PA/Ao) ratio on CT scans, an indirect sign that has been reported…
People newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) who have lower exercise capacity and poorer breathing efficiency during exercise tend to also report more severe anxiety and depressive symptoms, according to a new study in China. “The present findings … support greater attention to psychological symptoms during the…
Artificial intelligence (AI) tools using machine learning may help doctors predict how a pulmonary arterial hypertension (PAH) patient’s ability to walk might change over the next year, a study from Germany found. The researchers said more study is needed before the machine learning model, which uses clinical data available…
Note: This story was updated Sept. 30, 2026, to clarify that the Chiesi Group is no longer collaborating with Gossamer Bio in the development, regulatory activities, or commercialization of seralutinib. Gossamer Bio has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of seralutinib, an…
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Winrevair (sotatercept-csrk), an approved injection therapy for adults with pulmonary arterial hypertension (PAH) marketed by Merck. The most notable change in this update is the addition of a contraindication (a…
A national database study found substantial variation in how clinicians manage people hospitalized with pulmonary arterial hypertension (PAH) who presented with shock, a life-threatening lack of blood flow to the body’s organs. Researchers identified 25 different initial treatment strategies involving vasoactive medications, drugs that adjust blood pressure and heart…
Measurements that look at the interplay between the pulmonary arteries and the heart may help predict the likelihood of survival among people with all forms of pulmonary hypertension (PH), according to a study. These measurements were able to predict mortality risk even in mild PH, whereas conventional disease severity…
Mosliciguat, an inhaled treatment being developed by Pulmovant, was well tolerated and more effective than a placebo at improving blood flow through the lungs of adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), supporting its move into Phase 3 clinical testing, which is already underway. That’s…
